ZYME250117C22500
- 0.00
- 0.000.00%
Zymeworks Newsroom
Insider Purchase: Director at $ZYME (ZYME) Buys 11,958 Shares
Ecor1 Capital Increases Stake in Zymeworks With $1.88 Million Purchase
(SEC Amendment) Zymeworks(ZYME.US) 10% Shareholder Buys US$17.54 Million in Common Stock
Wells Fargo Downgrades Zymeworks(ZYME.US) to Hold Rating, Raises Target Price to $14
Express News | Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $14
Biggest Stock Movers Tuesday: ZYME, EVGO, and More
Zymeworks Raised to Overweight From Neutral by JP Morgan
J.P. Morgan Upgrades Zymeworks(ZYME.US) to Buy Rating, Raises Target Price to $18
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Express News | Zymeworks Inc : JP Morgan Raises to Overweight From Neutral; Raises Target Price to $18 From $12
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Maintains Target Price $28
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
More Unpleasant Surprises Could Be In Store For Zymeworks Inc.'s (NASDAQ:ZYME) Shares After Tumbling 27%
Zymeworks Advances Oncology and Expands Therapeutic Reach
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress In Oncology Programs And Expansion Into Autoimmune And Inflammatory Diseases December 12, 2024 At 8:30 Am EST
Catalyst Watch: Goldman Sachs Finance Conference; Adobe, CostCo Earnings
Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
Zymeworks Hold Rating: Balancing FDA Milestones With Market Valuation and Future Risks
Leerink Partners Maintains Zymeworks(ZYME.US) With Buy Rating, Raises Target Price to $26
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK